RayKnowChina Research Map
Shortlist0

RecruitingOesophageal squamous cell carcinomaPhase 2/Phase 3

Registered title, quoted from ClinicalTrials.gov

Optimizing Neoadjuvant Treatment Regimens for Locally Advanced Esophageal Squamous Cell Carcinoma

An open trial on oesophageal squamous cell carcinoma, registered on ClinicalTrials.gov. Led by Peking Union Medical College Hospital; 0 other hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 8 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Lead sponsorPeking Union Medical College Hospital北京协和医院BeijingHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT06907602, read on 8 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 9

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (9 points)Hide the checklist
  1. 18 years to Not stated; sex: all

    Registered eligibility fields

  2. Pathological confirmation of esophageal squamous cell carcinoma

    Inclusion criterion 3

  3. Endoscopic ultrasound, enhanced CT scan of the neck, chest, and abdomen, and esophageal magnetic resonance imaging evaluate as T3 or resectable T4 PET/CT、 Cervical, thoracic, and abdominal enhanced CT evaluation of N0 or N+

    Inclusion criterion 4

    T staging evaluation is T1/T2

    Exclusion criterion 1

  4. Previous autoimmune disease requiring systemic treatment within 2 years

    Exclusion criterion 7

  5. ECOG score 0 or 1

    Inclusion criterion 8

  6. Absolute neutrophil count ≥ 1.5 × 109/L

    Inclusion criterion 10

    Platelets ≥ 100 × 109/L

    Inclusion criterion 11

    Hemoglobin ≥ 11g/L

    Inclusion criterion 12

    ALT ≤ 2 times the upper limit of normal value

    Inclusion criterion 13

    Creatinine clearance rate (Cockroft) ≥ 50ml/min

    Inclusion criterion 15

  7. PET/CT and other evaluations show distant metastasis (M1)

    Exclusion criterion 2

  8. Previous HIV, HBV, or HCV infections

    Exclusion criterion 13

  9. Planned pregnancy or patients during pregnancy or lactation

    Exclusion criterion 3

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT06907602, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • male or female
  • Age ≥ 18 years old
  • Pathological confirmation of esophageal squamous cell carcinoma
  • Endoscopic ultrasound, enhanced CT scan of the neck, chest, and abdomen, and esophageal magnetic resonance imaging evaluate as T3 or resectable T4 PET/CT、 Cervical, thoracic, and abdominal enhanced CT evaluation of N0 or N+
  • No clear distant metastasis (M0) and only cervical or supraclavicular lymph node metastasis (M1a)
  • Tumor longitudinal diameter ≤ 10cm
  • The tumor did not involve the dentate line
  • ECOG score 0 or 1
  • No hematological diseases, no liver or kidney dysfunction
  • Absolute neutrophil count ≥ 1.5 × 109/L
  • Platelets ≥ 100 × 109/L
  • Hemoglobin ≥ 11g/L
  • ALT ≤ 2 times the upper limit of normal value
  • TBil ≤ 1.5 times the upper limit of normal value
  • Creatinine clearance rate (Cockroft) ≥ 50ml/min
  • Obtain informed consent

Exclusion Criteria:

  • T staging evaluation is T1/T2
  • PET/CT and other evaluations show distant metastasis (M1)
  • Planned pregnancy or patients during pregnancy or lactation
  • History of previous chemotherapy, radiation therapy, or immunotherapy
  • Previous severe coronary heart disease and heart failure (NYHA grade III/IV)
  • Previous pulmonary interstitial fibrosis or severe pulmonary dysfunction that cannot tolerate surgery
  • Previous autoimmune disease requiring systemic treatment within 2 years
  • Previous immunodeficiency diseases or the need for systemic steroid replacement therapy
  • Previous motor or sensory neurotoxic diseases
  • Previous mental illness
  • Potential diseases that may affect patients' ability to receive planned treatment, such as drug allergies
  • Acute infectious diseases requiring systemic treatment
  • Previous HIV, HBV, or HCV infections
  • Previously received stem cell or solid organ transplantation

Quoted from ClinicalTrials.gov, NCT06907602, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT06907602, read on 8 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT06907602